enGene Therapeutics (ENGN) Cash Flow: Operating & Free Cash Flow

enGene Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for enGene Therapeutics Inc. (ENGN) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Operating Activities
Net Income	-117.30	-55.14	-99.92	-24.46	-23.44
Depreciation & Amortization	0.51	0.32	0.18	0.24	0.27
Stock Based Compensation	9.65	5.32	3.45	0.12	0.44
Change in Working Capital	9.74	0.10	-0.52	2.17	-1.04
Change in Accounts Receivable	-0.60	2.01	-1.01	0.14	0.30
Change in Accounts Payable	4.94	0.47	0.37	-0.20	0.11
Change in Other Working Capital	5.39	0.97	0.12	0.03	-1.44
Other Operating Activities	-1.83	0.97	72.07	4.34	7.79
Net Cash from Operating Activities	-99.24	-48.28	-24.74	-17.59	-15.98
Investing Activities
Capital Expenditures	-1.49	-0.93	-0.32	-0.15	-0.25
Purchases of Investments	-160.84	-125.03	0.00	0.00	0.00
Sales/Maturities of Investments	137.19	0.00	0.00	0.00	0.00
Other Investing Activities	0.00	0.00	0.00	0.00	0.00
Net Cash from Investing Activities	-25.14	-125.95	-0.32	-0.15	-0.25
Financing Activities
Debt Repayment	-0.70	-9.45	33.27	-1.01	7.07
Common Stock Issued	2.22	260.15	56.89	0.01	0.01
Other Financing Activities	0.00	-13.58	-4.01	-0.44	15.44
Net Cash from Financing Activities	1.52	265.72	86.15	27.97	22.53
Summary
Effect of Forex Changes on Cash	0.00	0.00	0.00	-0.81	0.10
Net Change in Cash	-122.85	91.48	61.09	9.42	6.39
Cash at Beginning of Period	173.00	81.52	20.43	11.02	4.63
Cash at End of Period	50.15	173.00	81.52	20.43	11.02
Free Cash Flow	-100.72	-49.21	-25.06	-17.75	-16.23
Supplemental Disclosures
Interest Paid	2.29	1.93	-	0.62	-

Source: Company financial statements from annual and quarterly filings. Data as of Jul 31, 2026. Data sources and methodology

Frequently Asked Questions About enGene Therapeutics Cash Flow

What is enGene Therapeutics's free cash flow?

enGene Therapeutics had negative free cash flow of $100.72M in fiscal 2025 (fiscal year ended Oct 31, 2025), operating cash flow of −$99.24M minus $1.49M of capital expenditures.

How much does enGene Therapeutics spend on capital expenditures?

enGene Therapeutics spent $1.49M on capital expenditures in fiscal 2025, compared with $925.00K a year earlier.

Does enGene Therapeutics pay dividends or buy back shares?

enGene Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition